Quick Overview: The Targeted Agent and Profiling Utilization Registry (TAPUR) study is evaluating molecularly targeted cancer drugs and ... Jason R Williams, MD, DABR Chief of Interventional Oncology Learn more  ... As the dust settles on this year's virtual edition of the annual meeting of the American Society of

Asco S First Ever Clinical - Detailed Overview & Context

The Targeted Agent and Profiling Utilization Registry (TAPUR) study is evaluating molecularly targeted cancer drugs and ... Jason R Williams, MD, DABR Chief of Interventional Oncology Learn more  ... As the dust settles on this year's virtual edition of the annual meeting of the American Society of Oncology is one of the fastest-moving categories, Moh'd Khushman, MD, Washington University, St. Louis, MO, explores key takeaways from the Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant ...

The purpose of this podcast is to educate and to inform. This is not a substitute When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments ...

Photo Gallery

ASCO's First-Ever Clinical Trial: The TAPUR Study
ONCOassist Heads to ASCO 2026 for the First Time
First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable Hepatocellular Carcinoma
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
ASCO 2023, American Society of Clinical Oncology
Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025
An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last: Lessons on...
The First Hero: A Son Reflects on His Father’s Illness
ASCO's Online Clinical Educators Forum 2025
FirstWord Pharma PLUS ASCO 2020 Review
Introduction to the TAPUR Study, with Richard Schilsky, MD, FACP, FASCO
Sneak preview of ASCO: Clinical presentation with practice-changing potential
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored